Antimicrobial Activity of Pediococcus pentosaceus PMY2 Against Multidrug-Resistant Pathogens

Area of Science:

• Microbiology
• Immunology
• Pharmacology

Background:

• Multidrug-resistant (MDR) pathogens present a significant threat to effective infection treatment.
• Pediococcus pentosaceus (P. pentosaceus) possesses known antimicrobial properties, but its efficacy against MDR strains requires further investigation.
• Limited research exists on P. pentosaceus's potential to combat emerging antibiotic resistance.

Purpose of the Study:

• To evaluate the antimicrobial activity of Pediococcus pentosaceus PMY2 against MDR pathogens.
• To assess the anti-inflammatory and cytotoxic effects of P. pentosaceus PMY2.
• To determine the potential of P. pentosaceus PMY2 as a natural antimicrobial agent.

Main Methods:

• In vitro evaluation of antimicrobial activity, including Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) against Staphylococcus aureus (S. aureus) and Methicillin-resistant S. aureus (MRSA).
• Assessment of biofilm inhibition by P. pentosaceus PMY2.
• In vitro analysis of anti-inflammatory effects using RAW 264.7 macrophages, measuring nitric oxide (NO), IL-6, and TNF-α levels.
• Cytotoxicity assessment of P. pentosaceus PMY2's cell-free supernatant (CFS).

Main Results:

• P. pentosaceus PMY2 demonstrated significant antimicrobial activity against S. aureus and MRSA, with MIC values of 0.31 mg/mL.
• Biofilm formation was substantially inhibited by P. pentosaceus PMY2 at MIC levels (62.2% for S. aureus, 51.5% for MRSA).
• CFS from P. pentosaceus PMY2 exhibited low cytotoxicity and potent anti-inflammatory effects, significantly reducing NO, IL-6, and TNF-α production.

Conclusions:

• Pediococcus pentosaceus PMY2 displays robust antimicrobial and anti-inflammatory properties against MDR pathogens.
• The findings highlight the potential of P. pentosaceus PMY2 as a natural antimicrobial agent for addressing antibiotic resistance.
• PMY2 CFS is a promising candidate for developing novel therapeutic strategies against resistant bacterial infections.